CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors by Chrystal Paulos, Mary Jo Turk, Megen C Wittling, Yina H Huang, Asmaa O Mohamed, David Tyler Boone, Shannon L Ferry, Melanie C Peck, Alicia M Santos, Haille E Soderholm

“…CD4 depletion and S233-armored CAR T cell combination therapy synergized to increase endogenous memory T cells.Conclusions Unarmored TRP-1-specific or NKG2D CAR T cells have intrinsic stem-like properties and differentiate into memory T cell subsets but are non-protective against primary or secondary tumors. …”
Get full text

Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content by Baohua Luo, Qingling An, Jingyu Lei, Dengxu Tan, Xiaoqiu Liu, Hui Li, Yong Zhao, Jing Qin, Caiqin Zhang, Yongbin Zhang, Changhong Shi

“…Furthermore, metabonomics showed that the combination therapy significantly increased the abundance of the metabolite prostaglandin D2 (PGD2), which was most likely related to the increased abundance of Desulfovibrio fairfieldensis. …”
Get full text

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model by Etienne Vignaud, Sylvain Goutelle, Charlotte Genestet, Jérôme Guitton, Sabine Cohen, Chloé Bourg, Aurore Durand, Laura Lebouteiller, Albin Bernard, Caroline Richet, Oana Dumitrescu, Elisabeth Hodille

“…Abstract Background Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is recommended, but its antimicrobial activity and clinical efficacy is uncertain. …”
Get full text

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma by Victoria Jennings, Kevin Harrington, Hardev Pandha, Alan Melcher, Adel Samson, Fiona Errington-Mais, Victoria Roulstone, Eva Crespo-Rodriguez, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Martin McLaughlin, Malin Pedersen, Richard Vile, Joan Kyula, Jehanne Hassan, Lizzie Appleton, Charleen ML Chan Wah Hak, Gabby Baker, Edward Armstrong, Matthew Chiu, Masahiro Ono

“…This immune data was used to inform the selection of ICI for triple combination therapy, the effects of which were then further characterized using transcriptomics.Results Adding BRAFi treatment to HSV improved anti-tumor effects in vivo but not in vitro. …”
Get full text

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation by Chang Dong Yeo, Dong Won Park, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, Chang‐Min Choi, In‐Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young‐Chul Kim, Tae Won Jang, Kye Young Lee, Seung Hun Jang, Seung Joon Kim, for the Korean EGFR Registry Investigators

“…The primary endpoint is disease‐free survival in patients who have undergone radical therapy (surgery and radiotherapy) or progression‐free survival in those receiving targeted therapy (first, second, and subsequent lines), chemotherapy (first and subsequent lines), combination therapy, and palliative/maintenance therapy according to stages of EGFR‐mutated NSCLC. …”
Get full text

Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody by Liqiu Ma, Yang Li, Yoshimitsu Sakamoto, Lin Xie, Saaya Suzuki, Yukari Yoshida, Li Sui, Gang Guo, Jialing Wen, Wangcai Ren, Kazuhiro Kakimi, Kensuke Osada, Akihisa Takahashi, Takashi Shimokawa

“…Conclusion: Our findings suggest that there is an optimal dose range for the abscopal effect generated with the CIRT combined with anti-CTLA4 antibody, and it highlights a new opportunity for increased induction efficiency of the abscopal effect of combination therapy.…”
Get full text

Local Exosome Inhibition Potentiates Mild Photothermal Immunotherapy Against Breast Cancer by Qian Chen, Yanan Li, Jiameng Hu, Zhenyu Xu, Shengyi Wang, Naicong Cai, Mengjiao He, Yifang Xiao, Yuan Ding, Mengjuan Sun, Chunjiayu Li, Yiyang Cao, Zhongyuan Wang, Fang Zhou, Guangji Wang, Chen Wang, Jiasheng Tu, Haiyang Hu, Chunmeng Sun

“…The findings indicate that this local combination therapy remodels the immunosuppressive TME through exosome inhibition and enhanced immune cell infiltration, while also boosting T‐cell activity to trigger systemic antitumor immunity, showcasing the remarkable efficacy of this combination strategy in eradicating cold tumors.…”
Get full text

The role of artificial intelligence and machine learning in predicting and combating antimicrobial resistance by Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Muhammad Shafiq, Wenjie Fang, Rahat Ullah Khan, Mujeeb Ur Rahman, Xiaohui Li, Qiao-Li Lv, Bin Xu

“…These models can provide insights into the discovery of novel antimicrobials, the repurposing of existing drugs, and combination therapy through the analysis of their molecular structures. …”
Get full text

Engineering dual-driven pro-angiogenic nanozyme based on porous silicon for synergistic acceleration of burn infected wound healing by Wei Duan, Yue Gao, Ruru Xu, Sheng Huang, Xueqian Xia, Jingwen Zhao, Longhuan Zeng, Qiaolin Wei, Jia-Wei Shen, Jianmin Wu, Yongke Zheng

“…After exposure to 808 nm NIR laser, Pt@PSi-based photothermal and nano-catalytic combined therapy can achieve more than 95 % bacterial inhibition in vitro. …”
Get full text

Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A549 cells by Mansour S. Alturki, Nada Tawfeeq, Amal Alissa, Zahra Ahbail, Mohamed S. Gomaa, Abdulaziz H. Al Khzem, Thankhoe A. Rants'o, Mohammad J. Akbar, Waleed S. Alharbi, Bayan Y. Alshehri, Amjad N. Alotaibi, Fahad A. Almughem, Abdullah A. Alshehri

“…This study promisingly repurposed five drugs for KRAS mutant lung cancer, of which cefadroxil, and cortisone are particularly warranting further assessment either as a standalone or combination therapy while capreomycin is still an effective inhibitor for KRAS G12C mutant as evident from in silico and in vitro studies.…”
Get full text

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma by Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman

“…Tasquinimod significantly reduced the tumor load and increased the trabecular bone volume, which resulted in prolonged overall survival of MM-bearing mice in vivo.Conclusion Our study provides novel insights in the dual therapeutic effects of the immunomodulator tasquinimod and fosters its evaluation in combination therapy trials for MM patients.…”
Get full text

Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model by Sanghee Lim, Minhye Kwak, Jeonghan Kang, Melissa Cesaire, Kayen Tang, Robert W. Robey, William J. E. Frye, Baktiar Karim, Donna Butcher, Martin J. Lizak, Mahalia Dalmage, Brandon Foster, Nicholas Nuechterlein, Charles Eberhart, Patrick J. Cimino, Michael M. Gottesman, Sadhana Jackson

“…Finally, Ibrutinib, combined with doxil, prolonged median survival in rodent glioma models (27 vs. 16 days, p < 0.0001) with brain imaging showing a − 53% versus − 75% volume change with doxil alone versus combination therapy (p < 0.05). These findings indicate ibrutinib’s ability to increase brain endothelial permeability via junctional disruption and efflux inhibition, to increase BTB drug entry and prolong rodent glioma model survival. …”
Get full text

HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer by Xin Li, Peng Yang, Jin Gu, Nan Chen, Dengbo Ji, Jinhong Xia, Jinying Jia, Zhuang Sun, Mengyuan Shi, Hanyang Wang, Zhaoya Gao

“…HOXC6, overexpressed in BRAFV600E MSS CRC, regulates the MYC gene and contributes to treatment resistance, tumor growth, and metastasis. Moreover, the combination therapy demonstrated the ability to enhance antitumor immunity by synergistically upregulating the expression of immune activation-related genes, activating the cyclic guanosine monophosphate–adenosine monophosphate synthase/stimulator of interferon genes (cGAS/STING) pathway, and diminishing the tumor cells’ DNA mismatch repair capacity. …”
Get full text

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment by Tangyi Wang, Yadian Lei, Jingwei Sun, Li Wang, Yuxin Lin, Zhijing Wu, Shoude Zhang, Chengzhu Cao, Chengzhu Cao, Chengzhu Cao, Haiyan Wang, Haiyan Wang, Haiyan Wang

“…Overall, this study identifies NANOS1 as a new target for TNBC therapy and suggests a combination therapy approach that could enhance immunotherapy effectiveness and improve patient outcomes.…”
Get full text

Dry eye syndrome before corneal refractive surgery: the prevalence and pathogenesis-oriented therapy by N.V. Maychuk, I.S. Malyshev, M.R. Obraztsova

“…In 89 (88.1%) of 101 patients with evaporative DED the combination therapy consisting of the eyelid self-massage and two-phase cationic emulsion (oil-water), a mimic of tear film lipid layer, which contained the positively charged nanodrops of mineral oils dispersed in water, helped to normalize the ocular surface and tear production parameters, and thus enabled to perform CRS. …”
Get full text

Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medic... by V. T. Ivashkin, A. S. Trukhmanov, I. V. Maev, O. M. Drapkina, M. A. Livzan, A. I. Martynov, T. L. Lapina, A. V. Paraskevova, D. N. Andreev, O. P. Alexeeva, S. A. Alekseenko, A. Yu. Baranovsky, O. V. Zayratyants, O. Yu. Zolnikova, O. B. Dronova, I. L. Kliaritskaia, N. V. Korochanskaya, Yu. A. Kucheryavyy, S. N. Mammaev, M. F. Osipenko, S. S. Pirogov, E. A. Poluektova, D. E. Rumyantseva, R. G. Sayfutdinov, O. A. Storonova, Yu. P. Uspenskiy, I. B. Khlynov, V. V. Tsukanov, A. A. Sheptulin

“…PPIs are the drugs of choice in the treatment of both symptoms of gastroesophageal reflux disease and existing erosive esophagitis. Combination therapy Rebamipide with PPIs increases the effectiveness of relief of GERD symptoms, as well as reduces the frequency of relapses.Conclusion. …”
Get full text

ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2 by Dan Li, Wenjie Zhang, Ruiheng Wang, Shufeng Xie, Yixin Wang, Wanxin Guo, Zixuan Huang, Chaoqun Lu, Liang Shan, Han Liu, Lifang Ma, Xumin Hou, Zhenshu Xu, Jiayi Wang

“…Finally, tumor-bearing mice were used to validate the in vivo efficacy of the combination therapy strategy. Results Tumor cells treated with ferroptosis inducers showed increased sensitivity to Interferon gamma (IFN-γ) secreted by ROR1 CAR-T cells. …”
Get full text

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER st... by M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov

“…In PIONEER study the narlaprevir combination therapy was characterized by high efficacy, convenience of administration and favorable safety profile.…”
Get full text

Personalized approach in the management of women with heart failure with preserved ejection fraction and carbohydrate metabolism disorders by L.R. Petrovska, I.O. Kostitska, T.R. Petrovskyy, R.V. Petrovskyy

“…On the background of a 12-week course of combination therapy (daily dose of metformin is 2000 mg, dapagliflozin is 10 mg), there was a comparable decrease in carbohydrate metabolism indicators in the IIB group (IIA/IIB groups: HbA1C after treatment: ∆–1.75 %/∆–10.67 %, p < 0.001, respectively) and an improvement of laboratory and instrumental parameters of HFpEF (IIA/IIB groups after treatment: NT-pro-BNP content: ∆–5.96 %, p < 0.05/∆–13.65 %, p < 0.001; left ventricular ejection fraction: ∆+1.38 %/∆+9.00 %, p < 0.001, respectively). …”
Get full text

Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience by Yusuke Uchibori, Shuhei Kurosawa, Yuho Najima, Kyoko Haraguchi, Daichi Sadato, Chizuko Hirama, Yasutaka Sadaga, Kaori Kondo, Chika Kato, Satoshi Sakai, Yasuhiro Kambara, Fumihiko Ouchi, Masashi Shimabukuro, Atsushi Jinguji, Naoki Shingai, Takashi Toya, Hiroaki Shimizu, Takeshi Kobayashi, Hironori Harada, Hironori Harada, Yuka Harada, Yoshiki Okuyama, Noriko Doki

“…Azacitidine was the most frequently used combination therapy with DLI (n = 34). Regimens including venetoclax and FLT3 inhibitors have been commonly used since 2019 (n = 18). …”
Get full text